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Abstract
Introduction Several genetic risk models for breast and ovarian
cancer have been developed, but their applicability to specific
populations has not been evaluated. We used data from French-
Canadian families to evaluate the mutation predictions given by
the BRCAPRO and BOADICEA models. We also used this data
set to estimate the age-specific risks for breast and ovarian
cancer in BRCA1 and BRCA2 mutation carriers.
Methods A total of 195 families with multiple affected
individuals with breast or ovarian cancer were recruited through
the INHERIT (INterdisciplinary HEalth Research International
Team on BReast CAncer susceptibility) BRCAs research
program. Observed BRCA1 and BRCA2 mutation status was
compared with predicted carrier probabilities under the
BOADICEA and BRCAPRO models. The models were
assessed using Brier scores, attributes diagrams and receiver
operating characteristic curves. Log relative risks for breast and
ovarian cancer in mutation carriers versus population risks were
estimated by maximum likelihood, using a modified segregation
analysis implemented in the computer program MENDEL.
Twenty-five families were eligible for inclusion in the BRCA1
penetrance analysis and 27 families were eligible for the
BRCA2 penetrance analysis.
Results The BOADICEA model predicted accurately the
number of BRCA1  and  BRCA2  mutations for the various
groups of families, and was found to discriminate well at the
individual level between carriers and noncarriers. BRCAPRO
over-predicted the number of mutations in almost all groups of
families, in particular the number of BRCA1  mutations. It
significantly overestimated the carrier frequency for high
predicted probabilities. However, it discriminated well between
carriers and noncarriers. Receiver operating characteristic
(ROC) curves indicate similar sensitivity and specificity for
BRCAPRO and BOADICEA. The estimated risks for breast and
ovarian cancer in BRCA1 and BRCA2 mutation carriers were
consistent with previously published estimates.
Conclusion The BOADICEA model predicts accurately the
carrier probabilities in French-Canadian families and may be
used for counselling in this population. None of the penetrance
estimates was significantly different from previous estimates,
suggesting that previous estimates may be appropriate for
counselling in this population.
Introduction
BRCA1 and BRCA2 are the most important breast cancer
susceptibility genes identified to date. A recent meta-analysis
of 22 population-based studies of breast and ovarian cancer
BOADICEA = Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; BS = Brier score; CI = confidence interval; 
INHERIT = INterdisciplinary Health Research International Team; NCI = National Cancer Institute; ROC = receiver operating characteristic; VUS = 
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[1] estimated the risk for breast cancer by age 70 years in
BRCA1 and BRCA2 carriers to be 65% and 45%, respec-
tively. The corresponding ovarian cancer risks were 39% and
9%, respectively. A number of other studies have investigated
the penetrance of these mutations, and risks have been found
to vary by birth cohort, mutation position in the gene, ascertain-
ment criteria and population studied [1-13]. Having precise
estimates of these risks is important for counselling mutation
carriers, and such estimates are fundamental components of
cancer risk prediction models. Such models are currently
being used and developed for counselling high risk women in
clinical genetics centres [14-17].
Population isolates or founder populations provide a particular
challenge for risk models, because the frequency of mutations
may be altered by the occurrence of specific founder muta-
tions that may attain relatively high frequency. Notable exam-
ples of this are the founder BRCA1 and BRCA2 mutations in
the Ashkenazi Jewish population, and the founder BRCA2
population in Iceland [13,18-20]. The French-Canadian popu-
lation is an example of such a founder population. The province
of Quebec population includes about 6 million French-Cana-
dians, who are descendants of about 10,000 immigrants,
mostly from France, who settled in Nouvelle France between
1608 and 1760. Altogether, approximately 80% of these
founders still have descendants in Quebec today, and they
account for the major part of the contemporary French-Cana-
dian gene pool [21,22]. Founder mutations in both BRCA1
and BRCA2 genes have been characterized in French-Cana-
dian high-risk breast/ovarian cancer families [23-26].
A number of models that predict BRCA1 and BRCA2 muta-
tion carrier risks and/or breast and ovarian cancer risks have
been reported in the literature [14-16,27-29]. The BRCAPRO
model was developed using published data and assumes that
genetic susceptibility to breast and ovarian cancer is due to
mutations in BRCA1 and BRCA2. The program uses informa-
tion on first-degree and second-degree relatives to compute
the probability that an individual carries a mutation in these
genes [16,30]. The recently published BOADICEA (Breast
and Ovarian Analysis of Disease Incidence and Carrier Estima-
tion Algorithm) model was developed using a combination of
population-based families and families with multiple affected
individuals, mainly from the UK. It takes into account the simul-
taneous effects of BRCA1, BRCA2 and the residual familial
clustering of breast cancer not accounted by these genes,
which is assumed to be explained by a polygenic model [14].
The model can be used to compute age-specific cancer risks
and mutation carrier probabilities using information on breast
and ovarian cancer occurrence in families of any size or
structure.
In the present study we used data from families of French-
Canadian origin identified through the INHERIT (INterdiscipli-
nary HEalth Research International Team on BReast CAncer
susceptibility) BRCAs integrated clinical research program to
assess the BRCAPRO and BOADICEA models of genetic
susceptibility to breast cancer [14,16] and to investigate
whether these models are suitable for counselling women in
this population. We also used this data set to estimate the
risks for breast and ovarian cancer conferred by BRCA1 and
BRCA2 mutations.
Materials and methods
Ascertainment of families
High-risk French-Canadian breast and/or ovarian families were
recruited into a research project started in 1996, which sub-
sequently evolved into a large ongoing interdisciplinary
research program designated INHERIT BRCAs [31,32]. A
major component was to identify and characterize BRCA1
and  BRCA2  mutations in the French-Canadian population.
This integrated clinical research program was composed of a
network of referring clinicians across the province of Quebec.
Following pre-test education sessions and detailed analysis of
familial history, individuals were recruited if their family met one
or more of the following strict criteria: the family had at least
four individuals with breast and/or ovarian cancer diagnosed
at any age in first-degree or second-degree relatives; the fam-
ily had three first-degree relatives affected with breast and/or
ovarian cancer at any age; or the family carried a deleterious
mutation already identified in the BRCA1 or BRCA2 genes.
Eight additional families that did not meet those strict criteria
were recruited when the analysis of pedigrees was suggestive
of a genetic component (e.g. monozygotic twins affected with
breast cancer at an early age; four related individuals with
early-onset breast cancer; one case of male breast cancer
plus a woman affected with early breast cancer). All partici-
pants had to be at least 18 years of age and mentally compe-
tent. In most instances, the diagnoses of breast and/or ovarian
cancer were confirmed by examining a pathology report. Clini-
cians involved in the research program were responsible for
disclosure of the BRCA1/BRCA2 test result to participants.
Approval was obtained from eight ethics committees corre-
sponding to the various institutions participating in the
research program.
A total of 191 families were recruited before 1 January 2003,
and data from these families were used to assess the ability of
the models to predict BRCA1 and BRCA2 carrier probabili-
ties. Four additional families ascertained by July 2003 were
found to segregate BRCA1 and BRCA2 truncating mutations
and were included in the analyses to estimate penetrance, in
order to improve the precision of the penetrance estimates.
Mutation testing
Individuals were assumed to be BRCA1 or BRCA2 positive
only if they carried a clearly deleterious mutation. Carriers of
variants of unspecified significance (VUS) were assumed toAvailable online http://breast-cancer-research.com/content/8/1/R3
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be  BRCA1/BRCA2  negative for the purpose of these
analyses.
Once a signed informed consent form had been obtained from
each participant, 40 ml blood was drawn and genomic DNA
extracted using the guanidine hydrochloride-proteinase k
method [33] and the QIAmp Maxi blood kit (QIAGEN, Missis-
sauga, Canada), in accordance with the manufacturer's
instructions. Participants from families considered in the
present study were first tested for a panel of 18 truncating
mutations detected or reported in the French-Canadian popu-
lation. This screening led to the discovery of mutations in 52
families (seven distinct mutations), which accounted for 88%
of all positive families identified before July 2003. DNA sam-
ples from at least one individual from 113 of the families with
inconclusive  BRCA1/BRCA2  test results (i.e. no mutation
found in the first stage) were sent to Myriad Genetics Labora-
tories (Salt Lake City, UT, USA) for full-length BRCA1/
BRCA2 sequencing using their Comprehensive BRACAnaly-
sis®. No additional analysis was performed for 30 families.
Testing services were performed according to the Memoran-
dum of Understanding of the US National Cancer Institute
(NCI) for NCI-funded research testing services for BRCA1
and BRCA2 (project no. NCI 173). This second step screen-
ing approach led to the discovery of mutations in seven differ-
ent families (seven distinct mutations), leaving 106 families
with an inconclusive result [24]. DNA samples from 98 families
with an inconclusive result were tested at the Cancer Genom-
ics Laboratory at Québec City by multiplex ligation probe
amplification. These approaches failed to detect any deleteri-
ous rearrangement (Moisan AM, Fortin J, Dumont M, Samson
C, Bessette P, Chiquette J, Laframboise R, Lépine J,
Lespérance B, Pichette R, Plante M, Provencher L, Voyer P,
Goldgar D, Bridge P, Simard J. No evidence of BRCA1/2
genomic rearrangements in high risk French-Canadian breast/
ovarian cancer families, submitted, 2005). A confirmation test
was performed for each individual belonging to a BRCA1/
BRCA2  positive family on a second blood sample by the
Molecular Diagnostic Laboratory of Alberta Children's Hospi-
tal (Calgary, Alberta, Canada), under the responsibility of Dr
Peter Bridge. VUS were detected in 13 families without dele-
terious mutations.
Statistical methods
Penetrance estimation
We used data from the families in which deleterious BRCA1
or BRCA2 mutations were identified to estimate the breast
and ovarian cancer risks in carriers of such mutations. For
these calculations we considered only those families in which
at least one mutation carrier was identified and at least one fur-
ther family member had DNA testing after the mutation carrier
was identified. BRCA1 and BRCA2 families in which no mem-
ber was tested for mutations subsequent to the first identified
carrier were excluded (seven families). Twenty-five families
segregating BRCA1 mutations and 27 families segregating
BRCA2 mutations were eligible for inclusion in the analysis.
We used information on the mutation status and disease
occurrence in the family members to estimate the breast and
ovarian cancer incidence rates in mutation carriers. We used
the information available before 2003, with the exception of
information about four eligible families segregating a deleteri-
ous BRCA1/BRCA2 mutation, which were recruited by July
2003.
The parameters were estimated by maximum likelihood using
a modified segregation analysis implemented in the computer
program MENDEL [34]. We assumed a model in which a
female after birth was at risk for developing breast or ovarian
cancer, or was censored at death or the age at which she was
last observed. The disease incidence rates were assumed to
depend on the underlying genotype through a Cox propor-
tional hazards model λi(t) = λ0(t)RH(t), where λ0(t) is the base-
line incidence rate for noncarriers and RH(t) is the relative
hazard at age t for carriers compared with noncarriers.
Nonmutation carriers were assumed to be susceptible to the
population incidence rates for Quebec during 1978–1981
(International Agency for Research on Cancer, Cancer Inci-
dence in Five Continents, Volume V, IARC Scientific publica-
tions, Lyon, 1987). The models were parameterized in terms of
the age-specific log relative hazard for breast and ovarian can-
cer compared with the population risks. More details on this
method can be found in the report by Antoniou and coworkers
[1]. We also performed analyses in which the end-point of
interest was either breast or ovarian cancer. A single set of
incidence rates was derived representing the incidence of
either breast or ovarian cancer in BRCA1 or BRCA2 mutation
carriers. All analyses were performed separately for the
BRCA1 and BRCA2 positive families.
To correct for ascertainment, we employed the sequential
ascertainment correction scheme described by Cannings and
Thompson [35]. Because family ascertainment was through
multiple affected individuals with at least one family member
testing positive for mutations, we maximized the conditional
likelihood of all phenotypic and genotypic information in the
family given all disease phenotypes and the genotypic informa-
tion up to the point at which the first mutation carrier was
identified.
BRCA1 and BRCA2 carrier probabilities
To assess the consistency of the Quebec families with genetic
models that incorporate the effects of BRCA1 and BRCA2
mutations, we used the data to estimate the BRCA1  and
BRCA2 mutation carrier probabilities of the first screened indi-
vidual in each family. For this analysis we used data from the
191 families recruited between 1996 and 2003, and consid-
ered only those families in which mutation screening was car-
ried out in at least one family member. The families of
individuals who were recruited because of prior knowledge ofBreast Cancer Research    Vol 8 No 1    Antoniou et al.
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a mutation segregating within the family were excluded (three
in total), thus leaving a total of 188 families. For the purpose of
these predictions, the first individual in whom mutation screen-
ing was carried out was considered the proband, and predic-
tions were only made for these individuals. In some instances
a mutation was identified after screening several individuals in
the family, even though the first tested individual was found to
be a noncarrier. These subsequent rounds of testing were
ignored, because the predicted probabilities for subsequent
individuals would be altered by the fact that a mutation had not
been found previously. We used the information on breast and
ovarian cancer diagnosis in families that was available before
2003.
Mutation prediction models
BOADICEA is a computerized risk assessment program that
can be used to compute the probability of detecting a BRCA1
or BRCA2 mutation and the risks for developing breast or
ovarian cancer [14]. The model considers the occurrence of
breast and ovarian cancer within the family. In the current ver-
sion, only the first cancer in an individual is considered. Dis-
ease occurrence in males and cancers other than breast and
ovarian cancers are ignored. The model is a genetic model that
is implemented in the program MENDEL [34], so that families
of any size or structure can be included. In the model, BRCA1
mutations are assumed to have a population allele frequency
of 0.06% and BRCA2 mutations to have an allele frequency of
0.10%. The residual familial clustering not accounted for by
BRCA1 and BRCA2 mutations is assumed to be explained by
a polygenic model with a variance that decreases with increas-
ing age [14]. We used an updated version of the model in
which the cancer risks in both carriers and noncarriers also
depend on the year of birth of the individual (Antoniou and
coworkers, unpublished data). For example, the risk for breast
cancer by age 70 years is 46% for a BRCA1 carrier born
before 1920, but it is 59% if the carrier is born after 1950. For
these analyses, the sensitivity of mutation detection was
assumed to be 70% for BRCA1 and 80% for BRCA2 (Easton
D, based on Breast Cancer Linkage Consortium data; per-
sonal communication).
The BRCAPRO program computes the probability that an indi-
vidual carries a BRCA1 or a BRCA2 mutation based on infor-
mation provided on relatives as distant as second degree
[16,36]. The model assumes that genetic susceptibility to
breast cancer is entirely due to mutations in BRCA1  and
BRCA2. We used the version implemented in the BayesMen-
del software, which is a library of programs written in the R
programming environment [37,38]. BRCAPRO, as distributed
in BayesMendel, comes with various options for BRCA1 and
BRCA2 penetrance and allele frequencies. For our purposes
we assumed the non-Ashkenazi allele frequencies (BRCA1:
0.0006; and BRCA2: 0.00022). We also used the current
default penetrances of BRCAPRO for populations other than
Ashkenazi Jewish.
To provide a more direct comparison between the models, two
sets of predictions were carried out under the BOADICEA
model: taking into account the entire family as reported, which
we refer to as 'full pedigrees'; and taking into account only the
first-degree and second-degree relatives of the first screened
individual.
Model comparisons
The models were calibrated by comparing the observed and
expected numbers of mutations. The models were also evalu-
ated in terms of the Brier score (BS) [39]. This is a measure of
accuracy of the predictions that measures the total difference
between observing a mutation and the predicted probability of
detecting a mutation. This is defined as follows:
Where n is number of families, pi is the probability of detecting
a BRCA1 or BRCA2 mutation, and xi is 0 if the proband was
Table 1
Summary statistics for the 188 families used in predicting the mutation status of the first screened individual
Full pedigrees First- and second-degree relatives only
Mean number of individuals per family 27.9 15.9
Number of BC casesa 993 612
Number of OC cases 66 54
Number of bilateral BC cases 70 58
Cases with BC and OC 26 12
Number of male BC cases 19 11
Median age at BC diagnosis (years) 51 51
Median age at OC diagnosis (years) 57 58
aCorresponds to females only. BC, breast cancer; OC, ovarian cancer.
BC, breast cancer; OC, ovarian cancer.
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found not to carry a mutation and 1 if the proband was found
to carry a BRCA1 or BRCA2 mutation. The smaller the BS,
the closer are the predictions to the observed data. The signif-
icance of the score was evaluated by the means of the
Spiegelhalter z-statistic [40].
The models were also evaluated in terms of their ability to pre-
dict accurate probabilities (reliability), and the ability of the pre-
dictions to separate correctly the carriers and noncarriers
(resolution/discrimination). These were assessed in terms of
the attributes diagrams. This involved ranking the predicted
probabilities and then dividing them into quantiles. The aver-
age predicted probability was computed for each quantile and
this was then plotted against the observed mutation frequency
in the quantile. Ninety-five per cent confidence intervals (CIs)
for the observed frequencies were computed using a binomial
distribution.
Receiver operating characteristic (ROC) curves were used to
assess the specificity and sensitivity of the various models.
Sensitivity here is defined as the proportion of tested individu-
als with mutations with a detection or carrier probability higher
than a given value (cutoff), and specificity is the proportion of
individuals without mutations with a detection probability
lower than the cutoff. The ROC curves plot the sensitivity
against the specificity at all possible cutoffs and show the
trade-off between the two measures. The area under the ROC
curve is a measure of the accuracy of a model, such that the
higher the area, the more accurate is the model (an area of 1
represents a perfect fit, and an area of 0.5 represents no pre-
dictive value).
Results
BRCA1 and BRCA2 mutation prediction
A total of 191 families were recruited before January 2003.
Three of those families were recruited because of prior knowl-
edge of a mutation segregating within the family and were
therefore excluded from this analysis. Table 1 shows some
summary statistics for these families. Ninety one percent of
families were extended beyond second-degree relatives. In
104 families the first individual screened for mutations was
unaffected, in 73 families the first screened individual had
Table 2
Observed and predicted number of mutations in the first screened individual by cancer status
Cancer status Model BRCA1a BRCA2a Noncarriers
Unaffected Observed 3 5 96
BOADICEA
Full pedigrees 3.49 6.30 94.21
Second-degree relatives 2.46 4.10 97.44
BRCAPRO 10.74 4.20 89.06
Breast cancer Observed 6 12 55
BOADICEA
Full pedigrees 8.68 13.17 51.14
Second-degree relatives 7.42 8.75 56.83
BRCAPRO 26.29 10.90 36.97
Ovarian cancer Observed 5 2 4
BOADICEA
Full pedigrees 3.52 0.63 6.85
Second-degree relatives 2.27 0.41 8.31
BRCAPRO 5.12 0.56 5.32
Totals Observed 14 19 155
BOADICEA
Full pedigrees 15.69 20.10 152.21
Second-degree relatives 12.15 13.26 162.59
BRCAPRO 42.16 15.67 130.35
aNot mutually exclusive under BRCAPRO.Breast Cancer Research    Vol 8 No 1    Antoniou et al.
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developed breast cancer, and in the remaining 11 families the
first screened individual had developed ovarian cancer. Table
2 shows the predicted number of mutations in those individu-
als under the BOADICEA and BRCAPRO models. As
described in the Materials and methods section (above), BRC-
APRO considers only second-degree relatives whereas
BOADICEA allows for families of an arbitrary size and
structure.
Among all the first screened individuals, 14 BRCA1 mutations
and 19 BRCA2 mutations were identified. When information
on all reported relatives in each family was considered, the
total numbers of mutations predicted by BOADICEA were
close to the observed numbers: 15.69 for BRCA1 and 20.10
for BRCA2. However, the expected number of BRCA1 muta-
tions was somewhat lower than observed when only the sec-
ond-degree relatives were considered (12.15) and much
lower for BRCA2  (13.26 predicted versus 19 observed).
BRCAPRO over-predicted the total number of BRCA1 muta-
tions (42.16) and under-predicted the number of BRCA2
mutations (15.67). The Pearson χ2 goodness-of-fit test for
comparing the total number of observed mutations with the
predicted number was not significant for BOADICEA but was
highly significant for BRCAPRO (P = 6 × 10-6). When infor-
mation on all available relatives was used, the predicted num-
bers under BOADICEA were close to the observed numbers
for both unaffected probands and among the breast and
ovarian cancer patients. BRCAPRO over-predicted the
number of BRCA1 mutations among both unaffected individ-
uals and breast cancer cases.
Table 3 shows the predicted number of mutations by the
number of breast and ovarian cancer cases in the family diag-
nosed under age 70 years. The number of BRCA1  and
BRCA2 mutations predicted by BOADICEA when the 'full
pedigrees' were considered was close to the observed
number in each subcategory except among families with four
or more breast cancer cases, for which the number of pre-
dicted  BRCA1  mutation was higher than the number
observed (6.20 versus 2). When information on family mem-
bers was restricted to the second-degree relatives of the first
screened individual, the under-prediction of BRCA1  muta-
tions was mainly among families with at least three cases of
breast cancer and at least one case of ovarian cancer (3.12
expected versus 6 observed). The expected number of
BRCA1  mutations was also somewhat higher than the
observed number among families with at least four cases of
breast cancer cases and no ovarian cancer cases (4.11 versus
2). The under-prediction of BRCA2  mutations was mainly
within this category of families (8.60 expected versus 12
observed). BRCAPRO over-predicted the number of BRCA1
mutations in all categories, but especially among families with
at least four breast cancer cases and no ovarian cancer cases
(19.40 versus 2). Within the same family category, the number
Table 3
Observed and expected number of mutations among the first screened individuals by number of cancers in the family
Number of cancers, age under 70 years Model BRCA1 BRCA2 Noncarriers
Observed Expected Observed Expected Observed Expected
≥3 BC, ≥1 OC BOADICEA
Full pedigrees 9 6.92 4 3.80 21 23.28
Second-degree relatives 6 3.12 1 1.49 7 9.38
BRCAPRO 6 7.80 1 2.35 7 3.98
≥4 BC, 0 OC BOADICEA
Full pedigrees 2 6.20 14 14.75 90 85.05
Second-degree relatives 2 4.11 12 8.60 57 58.29
BRCAPRO 2 19.40 12 8.27 57 43.37
3 BC, 0 OC BOADICEA
Full pedigrees 0 0.82 1 1.20 25 23.97
Second-degree relatives 1 1.09 2 1.77 37 37.13
BRCAPRO 1 5.43 2 2.97 37 31.60
2 BC, any OC BOADICEA
Full pedigrees 3 1.75 0 0.34 19 19.91
Second-degree relatives 5 3.83 4 1.40 54 57.79
BRCAPRO 5 9.53 4 2.08 54 51.50
BC, breast cancer; OC, ovarian cancer.Available online http://breast-cancer-research.com/content/8/1/R3
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of  BRCA2  mutations was under-predicted (8.27 expected
versus 12 observed).
The BS for the probability of detecting a BRCA1 or a BRCA2
mutation under the BOADICEA model was 0.112 when data
from the 'full pedigrees' were used to carry out the predictions
and 0.118 when information was restricted to second-degree
relatives only. The null hypothesis that the BOADICEA predic-
tions are compatible with the observations was not rejected
when the full pedigrees were used but was rejected when fam-
ily history information was restricted to second-degree rela-
tives only (P  = 0.61 and P  = 0.02, respectively, using
Spiegelhalter's z-statistic). Under BRCAPRO the BS was
0.148 (P = 0.003).
Resolution and reliability
Figure 1 shows the attributes diagram for evaluating the relia-
bility and resolution of the models. In this case the predicted
carrier probabilities were ranked and divided into sextiles so
that each quintile contains 31 or 32 observations. For this pur-
pose the BRCAPRO carrier probabilities were multiplied by
0.80 to allow for reduced sensitivity of mutation testing (i.e.
assuming that only 80% of the mutations could be identified
with the screening methods used). Points on the 45° line indi-
cate both good reliability and resolution, whereas points above
the line suggest that a model makes under-confident predic-
tions and in effect provides poor discrimination and inaccurate
probabilities. Points below the line suggest good discrimina-
tion but inaccurate probabilities.
The average predicted probability in each sextile was very
close to the observed frequency under the BOADICEA model
when the 'full pedigrees' were considered, indicating that
under such circumstances the model discriminates between
carriers and noncarriers and it gives accurate probabilities.
When only the second-degree relatives were considered the
average predicted probability was slightly lower than the
observed frequency in each sextile, indicating somewhat lower
discrimination. However, the 95% CIs of the observed fre-
quencies for all sextiles include the average predicted proba-
bilities. BRCAPRO provided very good discrimination
between carriers and noncarriers, but it did not give accurate
probabilities, especially at the two upper sextiles. In these
cases the average predicted probabilities were much higher
than the observed frequencies and outside their 95% CIs.
The ROC curves under BOADICEA using the full pedigrees
and under BRCAPRO are shown in Fig. 2. The area under the
curve was 83% (95% CI 75–91%) under BRCAPRO and
slightly lower, at 81% (95% CI 73–90%), under BOADICEA.
However, the difference was not statistically significant. The
curves can be used to define cutoffs for referring individuals
for BRCA1 and BRCA2 mutation screening. Under BOADI-
CEA, if all individuals with mutation detection probability of
16% and over were referred for screening, a sensitivity of
approximately 82% would be achieved. To obtain the same
sensitivity under BRCAPRO, the mutation carrier probability
cut-point needs to be approximately 25%. At these cutoffs the
BOADICEA predictions are 69% specific and the BRCAPRO
predictions 64% specific. The positive predictive value of
BOADICEA was 36% and the negative predictive value 95%.
Figure 1
Attributes diagram Attributes diagram. Shown is an attributes diagram comparing the predicted carrier probabilities and the observed carrier frequencies for BRCA1 
and BRCA2 mutations combined. BOADICEA predictions were carried out using data from all reported family members and restricted to second-
degree relatives only. BRCAPRO predictions were adjusted for an 80% sensitivity for the mutation screening methods used. Each point represents 
a sextile of the data and 95% confidence intervals were computed assuming a binomial distribution.Breast Cancer Research    Vol 8 No 1    Antoniou et al.
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Under BRCAPRO the positive predictive value was 32% and
the negative predictive value was 94%. Carriers and noncarri-
ers were correctly classified 72% and 67% of the time under
BOADICEA and BRCAPRO, respectively.
Risks for breast and ovarian cancers
Table 4 shows the estimated cumulative risks for breast and
ovarian cancer in BRCA1 and BRCA2 mutation carriers. The
risks were estimated separately for BRCA1 and BRCA2 pos-
itive families. Twenty-five families were used in the BRCA1
analysis. The cumulative risk for breast cancer by age 50 years
was estimated to be 20% (95% CI 0–45%) and by age 70
years it was estimated to be 72% (95% CI 0–93%). The cor-
responding ovarian cancer cumulative risks were estimated to
be 1% (95% CI 0–10%) and 38% (95% CI 0–78%). When
the event of interest was defined to be either breast or ovarian
cancer, the cumulative risks for either cancer were estimated
to be 23% by age 50 years (95% CI 0–48%) and 83% by age
70 years (95% CI 34–96%). When the analyses were
restricted to the 18 families carrying the founder mutation
R1443X, the cumulative risk for breast cancer was estimated
to be 86% by age 70 years and the cumulative ovarian cancer
risk 54%.
Data from 27 families were used in the BRCA2 analyses. The
cumulative risk for breast cancer was estimated to be 21% by
age 50 years (95% CI 0–55%) and 75% by age 70 years
(95% CI 0–97%). The corresponding cumulative risks for
ovarian cancer were 0.4% (95% CI 0–2%) and 49% (95% CI
0–81%). The cumulative risk for developing either breast or
ovarian cancer was estimated to be 35% by age 50 years
(95% CI 0–64%) and 89% by age 70 years (95% CI 34–
98%). When only the 23 families segregating the BRCA2
founder mutation 8765delAG were used, the cumulative
breast cancer risk by age 70 was estimated to be 71% and the
corresponding ovarian cancer cumulative risk to be 51%.
Discussion
In the present study we used data from French-Canadian fam-
ilies included in the INHERIT program to evaluate the mutation
risk prediction models BOADICEA and BRCAPRO [14,16]
and to estimate the breast and ovarian cancer risks conferred
by BRCA1 and BRCA2 mutations. A total of 157 of the fami-
lies were screened for mutations using a three-step approach:
screening for the 18 known French-Canadian mutations, full
sequencing, and multiplex ligation probe amplification for
detecting large rearrangements. Eight families were screened
using only the first two steps and 30 families were only
screened for the known French-Canadian mutations.
However, the two additional steps detected only seven muta-
tions, and it is therefore likely that no more than one or two
mutations were missed.
Penetrance was estimated using data from families segregat-
ing BRCA1 and BRCA2 mutations. The breast cancer risk by
age 70 years was estimated to be 72% in BRCA1 mutation
carriers and 75% in BRCA2  mutation carriers. The corre-
sponding ovarian cancer risks were 38% and 49%, respec-
tively. These point estimates are similar to the risks derived in
previous studies conducted in families with multiple affected
individuals [2,3,41]. However, our estimates are associated
with very wide confidence intervals, and the present risks are
also not significantly different from those derived using families
identified through population-based series of breast or ovarian
cancer patients [1,4,6-8,42]. The large confidence intervals
are partly due to the relatively small number of mutation-posi-
Figure 2
ROC curves ROC curves. Shown are ROC curves for the BOADICEA and BRCAPRO predictions of carrying either a BRCA1 or a BRCA2 mutation. BOADI-
CEA predictions assumed all reported family members. ROC, receiver operating characteristic.Available online http://breast-cancer-research.com/content/8/1/R3
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tive families considered in the estimation (25 for BRCA1 and
27 for BRCA2) but most importantly are due to the strong
ascertainment correction. In our analyses we conditioned on
the phenotypes of all family members and the genotypes of all
individuals up to and including the first identified mutation car-
rier in the family. Therefore, the information contributing to the
analyses only came from individuals typed after the first muta-
tion carrier was identified. The precision of these estimates
may be improved by genotyping additional family members or
by adding newly identified mutation-positive families in the
analysis.
The BOADICEA and BRCAPRO genetic models for breast
cancer susceptibility were used to compute expected num-
bers of mutations within subcategories of families. Empirical
models such as the Myriad II model [29] and the Manchester
scoring system [43] were used in these comparisons because
they will be investigated in a future report (Simard and cowork-
ers, unpublished data). The predicted numbers of mutations
under BOADICEA were very close to the observed numbers
when information on all reported relatives was taken into
account. However, when only the second-degree relatives of
the proband were considered the model under-predicted
somewhat. This is consistent with the general principle that
risk predictions should, where possible, take into account all
known information.
The total number of mutations was significantly over-predicted
by BRCAPRO. This was due to the over-prediction of BRCA1
mutations in almost all categories, with an under-prediction of
the number of BRCA2  mutations. Even if the predicted
number of mutations is adjusted for the reduced sensitivity of
the mutation detection techniques used, BRCAPRO would
still over-predict the number of BRCA1 mutations. The over-
prediction of BRCA1 mutations does not seem to be due to
the mutation frequency or penetrance estimates used in the
models. The penetrance estimates used in the current imple-
mentation of BRCAPRO were the latest for non-Ashkenazi
carriers, which are lower than the Breast Cancer Linkage Con-
sortium estimates used in the initial implementation [2,3] and
are closer to the estimates used in BOADICEA, although they
are not cohort specific. As implemented here, both BOADI-
CEA and BRCAPRO use a BRCA1 mutation frequency of
0.06%. BOADICEA uses a higher BRCA2 mutation frequency
than does BRCAPRO (0.10% versus 0.02%). However, when
the BRCA2 frequency in BRCAPRO was assumed to be the
same as in BOADICEA, BRCAPRO over-predicts the number
of mutations for both BRCA1 and BRCA2 (predicted num-
bers: 29.42 and 38.18, respectively). Presumably, this
discrepancy results from the fact that BRCAPRO does not
model any of the residual familial clustering of breast cancer,
other than BRCA1 or BRCA2, so that individuals with moder-
ate family histories are assigned probabilities for being muta-
tion carriers that are too high.
The Brier scores also indicate that BRCAPRO is not accurate
in predicting individual carrier probabilities, whereas the
BOADICEA predictions are compatible with the observations.
On the other hand the ROC curves indicate that BRCAPRO
and BOADICEA both discriminate well between carriers and
noncarriers. Thus, BRCAPRO and BOADICEA perform simi-
larly in terms of ranking individuals by carrier probability, but
the absolute carrier probabilities are only reliable for
BOADICEA. To achieve comparable sensitivity and specificity,
the cutoffs under the two models are therefore quite different.
Users of the models must be aware of these issues when
deciding whether to refer an individual for testing on the basis
of carrier or mutation detection probabilities given by a partic-
ular model.
This is the first time the updated version of BOADICEA has
been used to evaluate its prediction of mutation status in an
independent data set. The version used here varies from the
previous reported model [14] in that the model had been refit-
ted using data from two additional population based studies
[44,45] and using a much larger number of BRCA1  and
BRCA2 mutation-positive families [1]. In this respect the pen-
etrance estimates in the latest version are more accurate.
Other differences include the use of annual incidence rates as
opposed to 5-year interval rates for both carriers and noncar-
Table 4
Estimated cumulative risks of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
Age (years) BRCA1 BRCA2
BC OC BC or OC BC OC BC or OC
30 3 0 4 0.3 0 0.4
40 13 0 14 13 0.2 26
50 20 (0–45) 1 (0–10) 23 (0–48) 21 (0–55) 0.4 (0–2) 35 (0–64)
60 71 38 83 33 49 55
70 72 (0–93) 38 (0–78) 83 (34–96) 75 (0–97) 49 (0–81) 89 (34–98)
Shown are percentage cumulative risks (95% confidence interval). BC, breast cancer; OC, ovarian cancer.Breast Cancer Research    Vol 8 No 1    Antoniou et al.
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riers, the use of rates that are cohort specific, and incorpora-
tion of a polygenic component with a variance that decreases
linearly with age. The familial relative risks predicted by this
model are closer to the observed risks than those predicted by
the previous version (Antoniou and coworkers, unpublished
data). BRCA2 mutations (and, to a lesser extent, BRCA1
mutations) are associated with increased risks for male breast
cancer, prostate cancer and pancreatic cancer, and several
other cancers have been reported to occur at increased fre-
quency in BRCA1 or BRCA2 carriers [11,46,47]. The risks for
other cancers are not taken into account by the current version
of BOADICEA. Incorporating such information into account is
likely to result in more accurate carrier probabilities and in bet-
ter discrimination between carriers and noncarriers, and we
are currently extending the model to include such information.
Even though the BOADICEA model was developed using data
from the UK, it seems to fit the occurrence of breast cancer in
French-Canadian high-risk families. As demonstrated earlier,
the penetrance estimates derived from these families are not
significantly different from those used in BOADICEA. The
good fit to these data suggests that the overall BRCA1 and
BRCA2 allele frequencies are comparable to those in the UK
population. This is supported by the fact that studies of preva-
lence of BRCA1 and BRCA2 mutations in French-Canadian
patients with breast and ovarian cancer unselected for family
history indicate similar prevalences of mutations as in the UK
population and much lower than the prevalence of mutations
among Ashkenazi Jewish women [44,45,48-50].
Conclusion
In the present study we estimated breast and ovarian cancer
risks conferred by BRCA1 and BRCA2 mutations in French-
Canadian families. These estimates are in line with previous
ones but they are associated with very large confidence inter-
vals. Additional families or further mutation testing in the fami-
lies will be necessary to obtain more reliable estimates for this
population. The results also suggest that the BOADICEA
model of genetic susceptibility fits the data well; therefore, in
the absence of reliable estimates, the penetrance functions
used in this model can be employed for counselling BRCA1
and BRCA2 mutation carriers in this population. Using infor-
mation on all available relatives may improve individual muta-
tion predictions as opposed to restricting information to
second-degree relatives only.
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